LYTIR

Company · VRXA

Veraxa Biotech AG

Name as listed on its exchange; filed with the SEC as Veraxa Biotech AG - Post de-SPAC.

Nasdaq's symbol directory lists VRXA on Nasdaq as “Veraxa Biotech AG - Ordinary Shares”.

In the 12 months to Nov 8, 2026: insiders bought on 5 occasions ($125K); 5 filings by holders of 5% or more.

All insider filings at the SEC

Insider purchases and sales, by month (last 12 months)Insider purchases: $125K in total; Insider sales: $0 in total.Aug: Insider purchases $83KOct: Insider purchases $43KDecJanFebMarAprMayJunJulAugSepOctNov
Insider purchases above the line: $125KInsider sales below: $0
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.

Insider trades · SEC Form 4

Those inside the hall

Open-market purchases and sales only. Legs one person filed for one day are combined.

Who traded

  1. Oliver Rolf Baumann bought on 1 day latest Aug 27, 2026 bought $75K
  2. Christoph Samuel Ziegler bought on 1 day latest Oct 20, 2026 bought $33K
  3. Marc Gruninger bought on 2 days latest Oct 28, 2026 bought $10K
  4. Christoph Rudiger Antz, Chief Executive Officer bought on 1 day latest Aug 27, 2026 bought $8K
Every trade (5)
  1. BUYMarc Gruninger bought Oct 28, 2026 9,133 shares filing $9K
  2. BUYMarc Gruninger bought Oct 27, 2026 867 shares filing $850
  3. BUYChristoph Samuel Ziegler bought Oct 20, 2026 30,000 shares filing $33K
  4. BUYOliver Rolf Baumann bought Aug 27, 2026 50,000 shares filing $75K
  5. BUYChristoph Rudiger Antz, Chief Executive Officer bought Aug 27, 2026 5,000 shares filing $8K

Large holders · SEC Schedules 13D and 13G

Five percent and over

Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G

  1. AQR Capital Management, LLC filed Aug 13, 2026 Schedule 13G/A passive filing 0.46%
  2. Deck David Lukas filed Jun 16, 2026 Schedule 13D may seek influence 25,502,836 shares filing 18%
  3. European Molecular Biology Laboratory filed Jun 16, 2026 Schedule 13D may seek influence 22,891,235 shares filing 16.2%
  4. Xlife Sciences AG filed Jun 15, 2026 Schedule 13D may seek influence 23,029,967 shares filing 16.3%
  5. Schoeni Gilbert Edgar filed Jun 15, 2026 Schedule 13D may seek influence 22,539,749 shares filing 15.9%

Sources: SEC EDGAR (Forms 4 and 144) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.